首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4316367篇
  免费   346430篇
  国内免费   14164篇
耳鼻咽喉   59817篇
儿科学   137917篇
妇产科学   112784篇
基础医学   664466篇
口腔科学   115880篇
临床医学   393100篇
内科学   780046篇
皮肤病学   107683篇
神经病学   361196篇
特种医学   168318篇
外国民族医学   515篇
外科学   663967篇
综合类   120638篇
现状与发展   24篇
一般理论   2676篇
预防医学   359015篇
眼科学   101632篇
药学   302653篇
  21篇
中国医学   11498篇
肿瘤学   213115篇
  2021年   57031篇
  2020年   36266篇
  2019年   59553篇
  2018年   75448篇
  2017年   57290篇
  2016年   63637篇
  2015年   76399篇
  2014年   111277篇
  2013年   177188篇
  2012年   131087篇
  2011年   137789篇
  2010年   128995篇
  2009年   129651篇
  2008年   123009篇
  2007年   131447篇
  2006年   139484篇
  2005年   134616篇
  2004年   134297篇
  2003年   124022篇
  2002年   112971篇
  2001年   150334篇
  2000年   145055篇
  1999年   134843篇
  1998年   70758篇
  1997年   66697篇
  1996年   64784篇
  1995年   60018篇
  1994年   54114篇
  1993年   50338篇
  1992年   96308篇
  1991年   92872篇
  1990年   89232篇
  1989年   87014篇
  1988年   80172篇
  1987年   78664篇
  1986年   74011篇
  1985年   73151篇
  1984年   61834篇
  1983年   55589篇
  1982年   46177篇
  1981年   43270篇
  1980年   40634篇
  1979年   53199篇
  1978年   44130篇
  1977年   38974篇
  1976年   36360篇
  1975年   36338篇
  1974年   39484篇
  1973年   37704篇
  1972年   35299篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
951.

Background

Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.

Patients and Methods

We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.

Results

Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.

Conclusions

FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients.  相似文献   
952.
Maternal and Child Health Journal - Background Prenatal substance use screening is recommended. The 4 P’s Plus screener includes questions on perceived problematic substance use in parents...  相似文献   
953.
954.
955.
ObjectiveClinical specialty societies recommend long-acting reversible contraceptives (LARCs) as first-line contraception for adolescent women. We evaluated whether a combined educational and process improvement intervention enhanced LARC placement in primary care within an integrated health care system.MethodsThe intervention included journal clubs, live continuing education, point-of-care guidelines, and new patient materials. We conducted a retrospective cohort study across 3 time periods: baseline (January 2013?September 2015), early implementation (October 2015–March 2016), and full implementation (April 2016–June 2017). The primary outcome was the proportion of LARCs placed by primary care clinicians among women aged 13 to 18 years compared with gynecology clinicians.ResultsKaiser Foundation Health Plan of Colorado cared for approximately 20,000 women aged 13 to 18 years in each calendar quarter between 2013 and 2017. Overall, LARC placement increased from 7.0 per 1000 members per quarter at baseline to 13.0 per 1000 during the full intervention. Primary care clinicians placed 6.2% of all LARCs in 2013, increasing to 32.1% by 2017 (P < .001), including 45.5% of contraceptive implants. Clinicians who attended educational sessions were more likely to adopt LARCs than those who did not (17.9% vs 6.4% respectively, P = .009). Neither overall LARC placement rates (relative risk, 1.9; 95% confidence interval, 0.7?5.6) nor contraceptive implant rates (relative risk, 3.0; 95% confidence interval, 0.9?9.8) increased significantly in clinicians who attended educational activities.ConclusionsThis multimodal intervention was associated with increased LARC placement for adolescent women in primary care. The combination of education and process improvement is a promising strategy to promote clinician behavior change.  相似文献   
956.
957.
958.
959.
李焱  翟凤霞 《陕西中医》2020,(5):660-662
妊娠期间,咳嗽不已,称"妊娠咳嗽",亦称"子嗽",孕妇咳嗽日久未见好转,咳嗽胸痛甚则咳而呕吐,或咳嗽剧烈或久咳不愈,可损伤胎气,导致堕胎、小产。笔者运用六经辨证治疗外感型中表寒里热证子嗽,认为此类患者病在太阳阳明,属于寒热错杂之表寒里热,采用《伤寒论》中方证麻杏甘石汤合止嗽散,使热从外泄,宣发卫气,散寒不助热、解表不伤正,故辨证论治取得了显著的疗效。同时子嗽治疗还需注意健脾固肾安胎,应将顾护胎元贯穿治疗妊娠咳嗽的始终。  相似文献   
960.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号